# Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors

> **NCT06975410** · PHASE1,PHASE2 · RECRUITING · sponsor: **Yuhan Corporation** · enrollment: 80 (estimated)

## Conditions studied

- EGFR Overexpression
- Locally Advanced Solid Tumor
- Metastatic Solid Tumor

## Interventions

- **DRUG:** YH32364

## Key facts

- **NCT ID:** NCT06975410
- **Lead sponsor:** Yuhan Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-12
- **Primary completion:** 2027-06
- **Final completion:** 2029-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06975410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06975410, "Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06975410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*